![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ADAMTS10 |
Gene summary for ADAMTS10 |
![]() |
Gene information | Species | Human | Gene symbol | ADAMTS10 | Gene ID | 81794 |
Gene name | ADAM metallopeptidase with thrombospondin type 1 motif 10 | |
Gene Alias | ADAM-TS10 | |
Cytomap | 19p13.2 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q6ZN14 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
81794 | ADAMTS10 | male-WTA | Human | Thyroid | PTC | 1.09e-02 | 7.70e-02 | 0.1037 |
81794 | ADAMTS10 | ATC13 | Human | Thyroid | ATC | 6.99e-29 | 5.22e-01 | 0.34 |
81794 | ADAMTS10 | ATC5 | Human | Thyroid | ATC | 4.31e-39 | 5.56e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | ![]() |
Stomach | SIM | ![]() |
Liver | NAFLD | ![]() |
Liver | Cirrhotic | ![]() |
Liver | HCC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00301986 | Thyroid | PTC | extracellular matrix organization | 124/5968 | 301/18723 | 3.75e-04 | 2.53e-03 | 124 |
GO:00430626 | Thyroid | PTC | extracellular structure organization | 124/5968 | 302/18723 | 4.38e-04 | 2.92e-03 | 124 |
GO:00452296 | Thyroid | PTC | external encapsulating structure organization | 124/5968 | 304/18723 | 5.96e-04 | 3.79e-03 | 124 |
GO:003019812 | Thyroid | ATC | extracellular matrix organization | 152/6293 | 301/18723 | 8.63e-10 | 2.24e-08 | 152 |
GO:004306212 | Thyroid | ATC | extracellular structure organization | 152/6293 | 302/18723 | 1.17e-09 | 2.94e-08 | 152 |
GO:004522912 | Thyroid | ATC | external encapsulating structure organization | 152/6293 | 304/18723 | 2.11e-09 | 5.08e-08 | 152 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADAMTS10 | SNV | Missense_Mutation | novel | c.1769G>A | p.Arg590Lys | p.R590K | protein_coding | deleterious(0) | benign(0.147) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
ADAMTS10 | SNV | Missense_Mutation | rs782743402 | c.2336G>A | p.Arg779Gln | p.R779Q | protein_coding | tolerated(0.13) | benign(0.278) | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
ADAMTS10 | SNV | Missense_Mutation | c.1429N>A | p.Glu477Lys | p.E477K | protein_coding | deleterious(0) | benign(0.056) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
ADAMTS10 | insertion | Frame_Shift_Ins | novel | c.680_681insGAAATTCCATCTCAAAA | p.Gln228LysfsTer10 | p.Q228Kfs*10 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |||
ADAMTS10 | SNV | Missense_Mutation | novel | c.2947G>A | p.Ala983Thr | p.A983T | protein_coding | tolerated(0.29) | benign(0.003) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD | |
ADAMTS10 | SNV | Missense_Mutation | novel | c.122N>C | p.Ile41Thr | p.I41T | protein_coding | tolerated(0.06) | possibly_damaging(0.779) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | |
ADAMTS10 | SNV | Missense_Mutation | novel | c.2578N>T | p.Ala860Ser | p.A860S | protein_coding | tolerated(0.42) | benign(0.293) | TCGA-GH-A9DA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ADAMTS10 | SNV | Missense_Mutation | novel | c.1003N>A | p.Gly335Ser | p.G335S | protein_coding | deleterious(0.01) | probably_damaging(0.97) | TCGA-HG-A2PA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Taxol | PD | |
ADAMTS10 | SNV | Missense_Mutation | c.121N>T | p.Ile41Phe | p.I41F | protein_coding | tolerated(0.08) | possibly_damaging(0.888) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | ||
ADAMTS10 | SNV | Missense_Mutation | c.3266N>A | p.Arg1089Gln | p.R1089Q | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-MY-A5BE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |